CD274 and liver cancer: For instance, immunotherapies, such as cell-programmed death ligand-1 (PD-L1) inhibitor atezolizumab in combination with anti-angiogenic bevacizumab, have been shown to achieve good efficacy in the therapy of unresectable liver cancer [3].